Moderna, Merck Report on Promising Melanoma Vaccine
Companies announced that the vaccine performed well in a small study of patients who had the cancer surgically removed
Diagnosis & Disease Information
QOL Up With Pembrolizumab vs Ipilimumab, HDI in Resected Melanoma
Quality of life favored the pembrolizumab arm vs standard-of-care arm receiving ipilimumab, high-dose interferon α 2b
Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
In phase 2 study, relatlimab and nivolumab combination immunotherapy resulted in pathologic complete response rate of 57 percent
USPSTF: Evidence Still Lacking for Routine Skin Cancer Screening
Current evidence is insufficient for assessing balance of benefits and harms of screening for asymptomatic teens, adults
Nivolumab Promising for Treatment of Advanced Cutaneous SCC
Robust antitumor activity and good tolerability observed in phase 2 study of nivolumab for first-line treatment of advanced cutaneous squamous cell carcinoma
Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma
Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition
Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC
In phase 2 study, about half of patients with resectable stage II to IV cutaneous squamous cell carcinoma had pathological complete response
FDA: Cases of Breast Implant-Related SCC, Various Lymphomas Reported
Following an initial extensive review, the Agency identified less than 20 cases of SCC and less than 30 cases of various lymphomas in the capsule around the breast implant.
Cancer Risk Higher for Men vs Women at Most Shared Anatomic Sites
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11 percent
